Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone

Cancer

Volumn 122, Issue 5, 2016, Pages 758-765

  Konstantinidis, Ioannis T ^a   Koerkamp, Bas Groot ^a   Do, Richard K G ^a   Gönen, Mithat ^a   Fong, Yuman ^a   Allen, Peter J ^a   D'Angelica, Michael I ^a   Kingham, T Peter ^a   Dematteo, Ronald P ^a   Klimstra, David S ^a   Kemeny, Nancy E ^a   Jarnagin, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

floxuridine (FUDR); hepatic arterial infusion; intrahepatic cholangiocarcinoma; survival; systemic chemotherapy

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; SORAFENIB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CONTINUOUS INFUSION; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAHEPATIC BILE DUCT; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CAMPTOTHECIN; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MITOMYCIN; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84958932960     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29824     Document Type: Article

References (36)

1. Shaib YH, Davila JA, McGlynn K, El-Serag HB,. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40: 472-477.
2. Park J, Kim MH, Kim KP, et al., Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver. 2009; 3: 298-305.
3. Valle J, Wasan H, Palmer DH, et al., Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-1281.
4. Endo I, Gonen M, Yopp AC, et al., Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; 248: 84-96.
5. de Jong MC, Nathan H, Sotiropoulos GC, et al., Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011; 29: 3140-3145.
6. Sullivan RD, Norcross JW, Watkins E Jr,. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med. 1964; 270: 321-327.
7. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D,. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2006; 17 (2 pt 1): 217-223.
8. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al., Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008; 113: 2119-2128.
9. Fiorentini G, Cantore M, Rossi S, et al., Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo. 2006; 20: 707-709.
10. Goere D, Deshaies I, de Baere T, et al., Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010; 251: 686-691.
11. House MG, Kemeny NE, Gonen M, et al., Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011; 254: 851-856.
12. Ducreux M, Ychou M, Laplanche A, et al., Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005; 23: 4881-4887.
13. Kemeny NE, Niedzwiecki D, Hollis DR, et al., Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006; 24: 1395-1403.
14. Kerr DJ, McArdle CS, Ledermann J, et al., Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003; 361: 368-373.
15. Mocellin S, Pilati P, Lise M, Nitti D,. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007; 25: 5649-5654.
16. Mancini R, Tedesco M, Garufi C, et al., Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res. 2003; 23: 1837-1841.
17. Kemeny N, Jarnagin W, Paty P, et al., Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005; 23: 4888-4896.
18. Yamashita T, Arai K, Sunagozaka H, et al., Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011; 81: 281-290.
19. Ueshima K, Kudo M, Takita M, et al., Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010; 78 (suppl 1): 148-153.
20. Cantore M, Mambrini A, Fiorentini G, et al., Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005; 103: 1402-1407.
21. Mambrini A, Guglielmi A, Pacetti P, et al., Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res. 2007; 27: 3009-3013.
22. Inaba Y, Arai Y, Yamaura H, et al., Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol. 2011; 34: 58-62.
23. Jarnagin WR, Schwartz LH, Gultekin DH, et al., Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009; 20: 1589-1595.
24. Kemeny NE, Schwartz L, Gonen M, et al., Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011; 80: 153-159.
25. Allen PJ, Nissan A, Picon AI, et al., Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005; 201: 57-65.
26. Eisenhauer EA, Therasse P, Bogaerts J, et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
27. Kemeny N, Capanu M, D'Angelica M, et al., Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009; 20: 1236-1241.
28. Kemeny NE, Jarnagin WR, Capanu M, et al., Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2011; 29: 884-889.
29. Patel T,. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33: 1353-1357.
30. Bridgewater J, Galle PR, Khan SA, et al., Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60: 1268-1289.
31. Welzel TM, Graubard BI, El-Serag HB, et al., Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5: 1221-1228.
32. Andre T, Tournigand C, Rosmorduc O, et al., Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004; 15: 1339-1343.
33. Malka D, Cervera P, Foulon S, et al., Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014; 15: 819-828.
34. Hezel AF, Deshpande V, Zhu AX,. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010; 28: 3531-3540.
35. Jiao Y, Pawlik TM, Anders RA, et al., Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45: 1470-1473.
36. Collins JM,. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984; 2: 498-504.